Robert Bookstein, M.D.
Rob is seconded from Illumina and brings experience in medicine, human genetics and cancer biology. Prior to joining the fund, he led a team responsible for diagnostics partnerships and was active in identifying and evaluating venture and M&A opportunities.
Prior to Illumina, Rob was a part of the corporate venture unit of Biogen Idec, where his role was to evaluate new investment opportunities in cancer therapeutics. Rob had his first entrepreneurial experience as a Research Fellow at Canji, a privately-held biotechnology company focused on cancer gene therapy that became a subsidiary of Schering-Plough. His laboratory work included cancer genetics, tumor suppressor genes, prostate cancer, cancer gene therapy, and cancer drug discovery.
Rob also has experience in academia as an assistant professor at the Institute of Biotechnology at the University of Texas Health Science Center and before that a post-doctoral fellow with Dr. Wen-Hwa Lee in the Department of Pathology at the University of California, San Diego (UCSD).
Rob earned his bachelors degree in biology from Revelle College, UCSD and his MD from the Yale University School of Medicine. He completed a residency in anatomic pathology at UCSD Medical Center.